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Bayer AG v. Schein Pharmaceuticals, Inc.:1 A 
Pharmaceutical Company’s Victory in Securing a Patent 
Monopoly over Ciprofloxacin2 
Glenna L. Gilbert** 
In 1980, Dr. Klaus Grohe, a scientist for Bayer, attended a 
conference in Japan where the structure of an antibiotic known 
as norfloxacin was disclosed.3  From the structure of 
norfloxacin, the broad-spectrum antibiotic ciprofloxacin (Cipro) 
can be manufactured by a simple substitution of a cyclopropyl 
group for an ethyl group.4  With this knowledge in hand, Dr. 
Grohe “hastened home from the conference determined to make 
such a compound.”5  Despite Dr. Grohe’s efforts, his standard 
methodology was unsuccessful in his attempted synthesis of 
Cipro.6  He could not construct the starting material needed for 
the intermediate chemical reaction.7  Therefore, he called upon 
a colleague, Dr. Klauke, who “successfully synthesized the 
precursor 2,4-dichloro-5-fluorobenzoyl chloride, the so-called 
‘Klauke compound,’ necessary to make [Cipro] via 
cycloaracyclation.”8  By using the Klauke compound, Dr. Grohe 
was able to synthesize the second intermediate in the synthesis 
of Cipro, known as 6-FQA, which he then successfully made 
into Cipro.9 
 
* This article is published online at http://mipr.umn.edu. 
 1. Bayer AG v. Schein Pharm., Inc., 301 F.3d 1306 (Fed. Cir. 2002). 
 2. “Ciprofloxacin is a relatively simple heterocyclic organic compound 
developed by Bayer . . . .”  Id. at 1309. 
** JD Candidate 2005, University of Minnesota Law School. 
 3. Id. 
 4. See id.  Cipro is used to treat a wide variety of bacterial infections in 
humans.  See CiproUSA at http://www.ciprousa.com/cipro_other/index.asp 
(last visited November 5, 2003). 
 5. Bayer, 301 F.3d at 1309. 
 6. Dr. Grohe succeeded in making numerous compounds similar in 
structure to ciprofloxacin, but failed at making Cipro with his standard 
methodology.  Id. at 1310. 
 7. See id. 
 8. Id. 
 9. Id. 
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In Bayer AG v. Schein Pharmaceuticals, Inc.,10 Bayer AG 
and Bayer Corporation, collectively known as “Bayer”, sued five 
companies collectively known as “Schein”11 for infringement of 
U.S. Patent No. 4,670,444 and Reexamination Certificate B1 
4,670,444, collectively known as the “‘444 patent.”12  The ‘444 
patent claims a class of compounds that includes Cipro.13  
However, the ‘444 patent was not the first filed patent that 
claimed Cipro.14  Seven other applications preceded the ‘444 
patent, four of which are foreign applications that are relevant 
to this case.15 
The five defendants16 in this case filed Abbreviated New 
Drug Applications (ANDAs) with the FDA, seeking “approval to 
market generic versions of [Cipro].”17  These ANDAs led Bayer 
to sue Schein for infringement of the ‘444 patent.18  On cross-
motions for summary judgment, Schein conceded infringement 
of the ‘444 patent but claimed that the ‘444 patent “is invalid 
based on the filing and issuance of the Chilean, South African, 
Spanish and Argentinean patents,19 because under 35 U.S.C. § 
102(d) those foreign patents are prior art that would invalidate 
the ‘444 patent.”20  Bayer argued that the ‘444 patent is 
 
 10. Id. 
 11. The five companies are Schein Pharmaceutical, Inc., Danbury 
Pharmacal, Inc., Reddy-Cheminor, Inc., Mylan Pharmaceuticals, Inc., and 
Mylan Laboratories Inc.  Id at 1308. 
 12. Id. 
 13. Id. at 1310. 
 14. Id. 
 15. Id. at 1310-11.  “Bayer filed the first relevant patent application in 
Chile on August 12, 1981.”  Id. at 1311.  The next day, Bayer filed the ‘560 
application in the United States, followed by “applications in South Africa 
(September 2, 1981), Spain (September 2, 1981), and Argentina (September 3, 
1981).”  Id.  The applications in Chile, South Africa, Spain and Argentina 
issued as patents between May and September of 1982.  Id.  On October 22, 
1982, after the issuance of the foreign patents, Bayer filed for a second United 
States application, the ‘112 application, as a continuation of the ‘560 
application.  Id.  Bayer subsequently abandoned the ‘560 application.  Id.  
Bayer then filed a third United States application, the ‘923 application, on 
May 29, 1984, as a continuation-in-part of the ‘112 application.  Id.  The ‘923 
application eventually “matured into the ‘444 patent, which [finally] issued on 
June 2, 1987.”  Id. 
 16. See supra note 11 and accompanying text. 
 17. Bayer, 301 F.3d at 1311. 
 18. See id.  “Bayer sued under 35 U.S.C. § 271(e)(2), alleging that filing 
the ANDAs infringed the ‘444 patent, and this suit stayed the ANDAs before 
the FDA.”  Id. 
 19. See supra note 15 and accompanying text. 
 20. Bayer, 301 F.3d at 1311. 
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entitled to the same filing date as the ‘560 application: August 
13, 1981.21  Schein countered by arguing that Bayer could not 
rely on the ‘560 application date because that application did 
not disclose “Grohe’s best mode of making ciprofloxacin as 
required by section 112.”22 
In Bayer, the district court granted Bayer’s motion for 
summary judgment, holding that “the ‘560 application satisfies 
the best mode requirement.”23  Schein subsequently appealed.24  
The Federal Circuit affirmed the lower court’s decision.25  The 
court held that “[b]ecause the ‘560 application complies with 
the disclosure requirements of section 112, the ‘444 patent can 
claim the benefit of the ‘560 application’s August 13, 1981, 
filing date.”26  Thus, because this date is within one year of the 
filing dates of the four foreign patents, the “issuance of 
those . . . patents does not invalidate the ‘444 patent under 
section 102(d).”27 
This Comment argues that, contrary to the Federal 
Circuit’s holding in Bayer, the ‘444 patent failed to comply with 
§ 112 and violated the best mode requirement when it failed to 
disclose fully the synthesis pathways for the precursors to 
Cipro.28  The first section of this Comment focuses on the 
legislative and case history behind the best mode requirement.  
The second section analyzes Bayer in detail, examining each of 
the Federal Circuit’s holdings in the case.  The final section 
then analyzes these holdings in light of the legislative purposes 
and case law precedent of the best mode requirement.  This 
Comment concludes that the Federal Circuit’s decision in Bayer 
both does not honor the purpose of the best mode requirement 
and does not follow its own precedent in prior cases concerning 
the best mode requirement. 
 
 21. Id.  Bayer alternatively argued “that under 35 U.S.C. § 119, it should 
be entitled to the filing date of the second German application, October 29, 
1981.”  Id.  See also supra note 15 and accompanying text. 
 22. Bayer, 301 F.3d. at 1311.  See also infra notes 34-35 and 
accompanying text. 
 23. Bayer, 301 F.3d. at 1311. 
 24. Id. at 1312. 
 25. Id. at 1323. 
 26. Id. 
 27. Id. 
 28. See supra notes 6-9 and accompanying text. 
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I. A HISTORICAL PERSPECTIVE OF THE BEST MODE 
REQUIREMENT 
A. THE BACKGROUND AND PURPOSES OF THE BEST MODE 
REQUIREMENT 
The United States Constitution grants Congress the power 
“[t]o promote the Progress of Science and useful Arts, by 
securing for limited Times, to Authors and Inventors, the 
exclusive Right to their respective Writings and Discoveries”.29  
In response, Congress enacted the Patent Act,30 which grants 
successful patentees a monopoly on their invention for a limited 
time.31  This monopoly is granted in exchange for the disclosure 
of the invention to the public and its eventual entry into the 
public domain.32 
However, a patent is only granted if the invention satisfies 
the substantive and procedural statutory requirements set out 
in Title 35 of the United States Code.33  Disclosure is one of 
these statutory requirements.34  This requirement is stated as 
follows: 
The specification shall contain a written description of the invention, 
and of the manner and process of making and using it, in such full, 
clear, concise, and exact terms as to enable any person skilled in the 
art to which it pertains . . . to make and use the same, and shall set 
forth the best mode contemplated by the inventor of carrying out his 
invention.35 
The disclosure requirement ensures that the public 
receives information on every essential aspect of the patented 
invention.36  Therefore, in essence, the public receives a “quid 
 
 29. U.S. CONST. art. I, § 8, cl. 8. 
 30. Patent Act of 1952, 35 U.S.C. §§ 1-376 (2000). 
 31. Richard M. Mescher, Patent Law: Best Mode Disclosure—Genetic 
Engineers Get Their Trade Secret and Their Patent Too?—Amgen, Inc. v. 
Chugai Pharmaceutical Co., 927 F.2d 1200 (Fed. Cir.), cert. denied, 112 S.Ct. 
169 (interim ed. 1991), 18 U. DAYTON L. REV. 177, 177 (1992); see also 
Christopher S. Marchese, Confusion, Uncertainty, and the Best Mode 
Requirement, 2 FED. CIR. B.J. 1, 4-6 (1992) (explaining that the exclusive 
rights conferred on an inventor by a patent includes licensing the invention 
and suing for infringement when others make, use, or sell the invention). 
 32. Mescher, supra note 31, at 177. 
 33. 35 U.S.C. § 101; Mescher, supra note 31, at 177. 
 34. Patent Act, 35 U.S.C. §112, ¶ 1 (2000). 
 35. Id. (emphasis added). 
 36. See Bonita Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 150-
52 (1989).  The Supreme Court stated: 
The federal patent system thus embodies a carefully crafted bargain 
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pro quo” for granting the monopoly to the inventor.37 
In a patent infringement suit, an alleged infringer can 
claim inadequate disclosure as a defense if a patent is issued 
without proper disclosure.38  The claim of inadequate disclosure 
includes the enablement39 and best mode defenses.40  This 
comment concerns the best mode requirement,41 which focuses 
on an “inventor’s particular embodiment or method of making 
the invention.”42 
The best mode requirement serves two main purposes.  
First, it “assures that the [patent] specification provides 
information to the public concerning what the invention is and 
how it can be practiced.”43  As Judge Rich explained in In re 
Nelson,44 the best mode requirement prevents an inventor from 
“disclos[ing] only what he knows to be his second-best 
embodiment, retaining the best for himself.” 45  The second 
 
for encouraging the creation and disclosure of new, useful, and 
nonobvious advances in technology and design in return for the 
exclusive right to practice the invention for a period of years. 
. . . We have long held that after the expiration of a federal patent, the 
subject matter of the patent passes to the free use of the public as a 
matter of federal law. 
Id. at 150-52. 
 37. See supra note 36 and accompanying text; see also Marchese, supra 
note 31, at 1 (expounding the purpose of the best mode requirement as 
“providing the public with full disclosure of inventors’ innovations in exchange 
for the exclusive rights that accompany the grant of a patent, while 
simultaneously preventing inventors from selfishly concealing their preferred 
embodiments.”) (footnotes omitted); Mescher, supra note 31, at 177 (stating 
that the inventor must fully disclose an invention to comply with statutory 
requirements). 
 38. Mescher, supra note 31, at 178 (“[I]f a patent is issued without proper 
disclosure it can be invalidated by the courts when an alleged infringer claims 
inadequate disclosure as a defense in an infringement suit.”); see also William 
F. Herbert, Failure to Disclose the “Best Mode”: What the Public Doesn’t Know 
Will Hurt Them, 64 J. PAT. OFF. SOC’Y 12, 25 (1982) (citing failure to disclose 
best mode as defense to non-infringement). 
 39. The purpose of the enablement requirement is to enable those skilled 
in the art to make and use the invention.  See In re Nelson, 280 F.2d 172, 184 
(C.C.P.A. 1960). 
 40. Mescher, supra note 31, at 178. 
 41. See infra notes 42-46 and accompanying text. 
 42. Marchese, supra note 31, at 9. 
 43. Mescher, supra note 31, at 181 (footnote omitted); see also Herbert, 
supra note 38, at 32. 
 44. In re Nelson, 280 F.2d 172. 
 45. Id.at 184; see also Gordon T. Arnold, Developing the Evidence on 
Patent Validity Issues, in 1 PATENT LITIGATION 1993 509, 536 (Tom Arnold et 
al. eds., 1993) (“‘One of the main reasons for the Patent Code is to encourage 
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purpose of the best mode requirement is to ensure that the 
disclosure of the invention provides the public with information 
that encourages current and future research in the “art of the 
invention” by the public and competitors.46 
B. LEGISLATIVE HISTORY OF 35 U.S.C. §112 
Congress adopted the first Patent Act in 1790.47  This act 
contained an enablement requirement48 as well as a 
requirement for the “whole truth.”49  The “whole truth” 
requirement, a forerunner of the best mode requirement,50 
formed the basis of the “whole truth” defense of patent 
infringement.51  When charged with patent infringement, 
Defendants could argue that the specification “‘does not contain 
the whole truth concerning his invention,’ or ‘contains more 
than is necessary to produce that effect described’ if either 
‘appear[ed] to have been intended to mislead, or shall actually 
mislead the public, so as the effect described cannot be 
 
inventors to make the necessary disclosures to permit others to advance the 
art; inventors may not keep secret information essential for that purpose.’”) 
(quoting Imperial Chem. Indus. v. Barr Lab., 22 USPQ2d 1906, 1907 (S.D.N.Y 
1992)); Marchese, supra note 31, at 9 (“The best mode disclosure requirement 
prevents inventors from selfishly concealing their preferred embodiments, 
which are developed before filing the application, thereby retaining the best 
for themselves.”) (footnote omitted). 
 46. Mescher, supra note 31, at 181; see also David Conlin, The Patent 
Application, in 2 PATENT PRACTICE 9, at 9-1 to 9-3 (Irving Kayton, ed., 1985) 
(listing important functions of the patent application, including “disclosure by 
which the public may learn what the invention is and how to practice it when 
the patent term expires”); Marchese, supra note 31, at 7 (“Through disclosure, 
the patent system introduces new designs and technologies into the public 
domain, and thereby increases the public store of knowledge and 
information.”). 
 47. Act of April 10, 1790, ch. 7, 1 Stat. 109-12; Thomas L. Irving et al., 
The Significant Federal Circuit Cases Interpreting Section 112, 41 AM. U. L. 
REV. 621, 624 (1992); Marchese, supra note 31, at 10. 
 48. The enablement requirement in the 1790 Patent Act required patent 
applicants to “file a specification describing the applicant’s invention to 
distinguish the invention from prior art and ‘to ensure a workman or other 
person skilled in [the] art’ could make, build, or use the invention.”  Marchese, 
supra note 31, at 10 (quoting Act of April 10, 1790, ch. 7, § 2, 1 Stat. 109). 
 49. Act of April 10, 1790, ch. 7, § 6, 1 Stat. 109.  See Marchese, supra note 
31, at 10 (stating that the 1790 Act provided “the forerunner of the best mode 
requirement” in the form of the whole truth defense that could be asserted in a 
patent infringement suit). 
 50. Marchese, supra note 31, at 10. 
 51. Act of April 10, 1790, ch. 7, § 6, 1 Stat. 109.  See also Irving, supra 
note 47, at 624 (for a discussion of the “whole truth” defense). 
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produced by the means specified.’”52 
In the Act of 1793,53 Congress added the requirement that 
applicants of mechanical inventions must “fully explain the 
principle, and the several modes in which he has contemplated 
the application of that principle.”54 
The “best mode” provision superseded the “several modes” 
provision in the Patent Act of 1870.55  However, as in the Act of 
1793,56 this best mode requirement only applied to machines.57  
The relevant section of the 1870 Act “provided that an inventor 
‘shall explain the principle [of the machine], and the best mode 
in which he has contemplated applying that principle so as to 
distinguish it from other inventions.’”58 
Finally, in the Patent Act of 1952, the best mode 
requirement was expanded to include all inventions59 and the 
best mode requirement replaced the whole truth defense.60  
Therefore, failure to disclose the invention is now a defense 
regardless of intent.61 
C. JUDICIAL INTERPRETATION OF THE BEST MODE 
REQUIREMENT 
1. The Early Cases Before the Establishment of the Federal 
Circuit Courts first recognized the purpose of the best mode 
requirement in In re Gay.62  The United States Court of 
Customs and Patent Appeals declared that the “sole purpose of 
[the best mode requirement] is to restrain inventors from 
 
 52. Irving, supra note 47, at 624 (quoting Act of April 10, 1790, ch. 7, § 6, 
1 Stat. 109) (alteration in orginal). 
 53. Act of February 21, 1793, ch. 11, 1 Stat. 318-23 (amended 1836). 
 54. Id. (emphasis added). 
 55. Irving, supra note 47, at 625 (discussing the 1870 amendments to the 
Act of July 8, 1870, ch. 230, §26, 16 Stat. 198, 201). 
 56. Act of February 21, 1793, ch. 11, 1 Stat. 318-23 (amended 1836). 
 57. See Marchese, supra note 31, at 12. 
 58. Id. (quoting Act of July 8, 1870, ch. 230, § 26, 16 Stat. 198, 201) 
(alteration in original). 
 59. Irving, supra note 47, at 626. 
 60. Marchese, supra note 31, at 13. 
 61. See Pasquale J. Federico, Commentary on the New Patent Act, 35 
U.S.C.A §§ 1-376 (1954), reprinted in 75 J. PAT. & TRADEMARK OFF. SOC’Y 
161, 216 (1993) (“Since intention to deceive the public was an element of [the 
whole truth] defense it was seldom raised; [therefore] failure to give a 
description of the invention as required by Section 112 is a defense without 
regard to intention”). 
 62. In re Gay, 309 F.2d 769 (C.C.P.A. 1962). 
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applying for patents while at the same time concealing from the 
public preferred embodiments of their inventions which they 
have in fact conceived.”63 
Another early case which was central to current judicial 
interpretations of the best mode requirement is Flick-Reedy 
Corp. v. Hydro-Line Manufacturing Co.64  This case concerned a 
seal for preventing leakage between the end of a cylinder and 
its head,65 and the court determined that “[t]he findings of fact 
and the patent specifications and claims ma[d]e clear that an 
essential element of the patent [was] the ‘sealing relation’ 
between the outer machined surface of the reduced thickness at 
the end of the tube and the outer surface of the recessed groove 
in the head.”66  The court also found that the specification 
stated that the outer surface of the reduced thickness section 
was made with a special tool.67  Furthermore, this special tool 
was not disclosed in the specifications or claims.68  Because of 
this nondisclosure, the Seventh Circuit Court of Appeals 
upheld the District Court’s holding that the patent was invalid 
under 35 U.S.C. § 112.69 
The First Circuit Court of Appeals then distinguished 
Flick-Reedy in International Telephone & Telegraph Co. v. 
Raychem Corp.70  In this case, the patent involved a wire 
insulation composed of a primary layer of a cross linked 
polyolefin and a secondary, outer layer of cross linked 
polyvinylidene fluoride.71  International Telephone & Telegraph 
claimed that the patent did not disclose the “precise chemical 
formulations” that Raychem used to produce its commercial 
wire.72  More specifically, Raychem did not disclose the “use of 
two copolymers in the polyethylene layer of the wire insulation” 
and “the formula of a secret, proprietary compound” added to 
 
 63. Id. at 772. 
 64. Flick-Reedy Corp. v. Hydro-Line Mfg. Co., 351 F.2d 546 (7th Cir. 
1965). 
 65. Id. at 550. 
 66. Id. 
 67. Id. 
 68. Id. 
 69. Id. at 551; see also supra notes 34-35 and accompanying text. 
 70. Int’l Telephone & Telegraph Corp. v. Raychem Corp., 538 F.2d 453, 
460 (1st Cir. 1976). 
 71. Id. at 454. 
 72. Id. at 459. 
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the outer layer.73  Raychem claimed that these omissions did 
not violate the best mode requirement since the copolymers and 
the secret proprietary compound did not change the qualities of 
the finished product.74  Instead, they were used to aid in the 
“extrusion of the plastics during the manufacturing process.”75  
In response, the First Circuit reiterated its previous 
interpretation of the best mode requirement as requiring the 
disclosure of “‘specific material[s] which will make possible the 
successful reproduction of the effects claimed by the patent.’”76  
The court concluded, however, that the undisclosed elements 
were not essential to the production of the patented wires; and 
therefore the patent was valid against a best mode defense.77  
In Flick-Reedy the special tool was essential,78 in International 
Telephone the copolymers were not essential to the invention 
claimed.79 Thus, the court appeared to make a distinction 
between essential materials and nonessential materials, 
holding that essential materials must be disclosed in order to 
satisfy the best mode requirement.80 
2. Cases From the Inception of the Federal Circuit to 1991 
The first major best mode case decided by the Federal 
Circuit was Christianson v. Colt Industries Operating Corp.81  
The court held that the best mode requirement relates to what 
is required to practice the claimed invention,82 not what is 
required for mass production and sales of the invention to 
customers.83  Therefore, after Christianson, a patentee could 
 
 73. Id. 
 74. Id. at 459-60. 
 75. Id. at 460. 
 76. Id.(quoting Dale Elec., Inc. v. R.C.L. Elec., Inc., 488 F.2d 382, 389 (1st 
Cir. 1973)). 
 77. Id. 
 78. See supra notes 64-69 and accompanying text. 
 79. Int’l Telephone & Telegraph, 538 F.2d at 460. 
 80. See supra notes 64-79 and accompanying text. 
 81. Christianson v. Colt Indus. Operating Corp., 822 F.2d 1544 (Fed. Cir. 
1987). 
 82. Id. at 1563. 
 83. See id.  “Christianson accused Colt of violating the best mode 
requirement because Colt failed to disclose the tolerances and mass production 
data necessary to make the claimed invention (a part for a rifle) 
interchangeable in a particular use (the M16).”  Arnold, supra note 45 at 565.  
The Christianson court stated that “[t]he patent system has conferred on Colt 
no exclusivity or economic advantage respecting Colt’s dimensions, tolerances, 
and drawings necessary for interchangeability.”  Christianson, 822 F.2d at 
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not base a best mode violation on unclaimed subject matter 
that was necessary for optimal production and sales of the 
claimed invention.84 
The next major case, Spectra-Physics, Inc. v. Coherent, 
Inc.,85 involved two of Coherent’s patents, the Hobart patent, 
which is directed to an ion laser structure and the Mefferd 
patent, which is directed to a method of fabricating the ion 
laser.86  Both patents stress the fact that the bond between the 
copper cups and the ceramic tube must be able to withstand 
“repeated heat cycling” in order for the laser to be reliable.87  To 
make the critical copper-ceramic bond, Wayne Mefferd 
developed a six-stage braze cycle involving the use of Titanium-
Copper-Silicon (TiCuSil) brazing.88  The patent specification did 
identify several techniques for attaching the copper cups to the 
ceramic tube including the TiCuSil blazing.89  However, details 
of the brazing cycle, were not adequately disclosed in either 
patent, nor was it known in the prior art.90  As a result, the 
Federal Circuit held that both patents were invalid because 
they did not disclose the best mode of carrying out the 
invention.91  According to the Federal Circuit, if the patent 
applicant “develops specific instrumentalities or techniques 
which are recognized at the time of filing as the best way of 
carrying out the invention, then the best mode requirement 
imposes an obligation to disclose that information to the public 
 
1563. 
 84. See Christianson, 822 F.2d at 1563; Irving, supra note 47, at 711 
(explaining the holding in Christianson). 
 85. Spectra-Physics, Inc. v. Coherent, Inc., 827 F.2d 1524 (Fed. Cir. 1987). 
 86. Id. at 1526. 
 87. Id. at 1529. 
 88. Id. at 1531 (“Mefferd’s six-stage cycle produced a reliable braze joint 
between the copper cups and the ceramic tube.  Because this approach worked, 
Coherent continued to use TiCuSil and . . . [did not] further experiment[] with 
soldering.”). 
 89. Arnold, supra note 45, at 545. 
 90. The court stated “[t]he appropriate question then is not whether the 
inventors disclosed TiCuSil brazing at all—they did—but whether TiCuSil 
brazing was adequately disclosed.”  Spectra-Physics, 827 F.2d at 1536 
(emphasis in original).  Furthermore, “[e]ven though there may be a general 
reference to the best mode, the quality of the disclosure may be so poor as to 
effectively result in concealment.”  Id.  The court then concluded “[t]he facts 
found by the district court . . . plainly demonstrate that the TiCuSil brazing 
technique used by Coherent was not adequately disclosed.”  Id.  The court also 
noted that “Coherent admits that its braze cycle is not disclosed in either 
patent nor is it contained in the prior art.”  Id. 
 91. Spectra-Physics, 827 F.2d at 1538. 
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as well.”92 
Crucial to the Federal Circuit’s opinion in Spectra-Physics 
was the fact that the prior art did not show how to use the 
TiCuSil technique that Coherent employed.93  This case “shows 
that at least some judges on the Federal Circuit want to see the 
disclosure of something more than the preferred structure.”94 
Following Spectra-Physics, the Federal Circuit stated in 
Randomex, Inc. v. Scopus Corp.:95 
Because not complying with the best mode requirement amounts to 
concealing the preferred mode contemplated by the applicant at the 
time of filing, in order to find that the best mode requirement is not 
satisfied, it must be shown that the applicant knew of and concealed a 
better mode than he disclosed.96 
Therefore, in order to find a best mode violation, it must be 
shown that the inventor possessed an undisclosed preferred 
embodiment at the time of filing of the patent application.97  In 
this case, the court also explained the best mode requirement 
in dicta: “if one should invent a new and improved internal 
combustion engine, the best mode requirement would require a 
patentee to divulge the fuel on which it would run best.  This 
patentee, however, would not be required to disclose the 
formula for refining gasoline or any other petroleum product.”98  
Randomex involved a patent for a portable apparatus for 
cleaning computer disk packs.99  The court viewed the cleaning 
solution “as a fluid for use with the claimed invention,” but “not 
as a limiting feature of the claims.”100  The cleaning solution 
was not “a part of the ‘essence’ of the invention.”101  In other 
words, the cleaning solution was the “fuel” that would run the 
disk, or “engine” of the invention.102 
In Dana Corp. v. IPC Ltd. Partnership,103 the patent 
 
 92. Id. at 1532. 
 93. Arnold, supra note 45, at 545-46. 
 94. Id. at 547. 
 95. Randomex, Inc. v. Scopus Corp., 849 F.2d 585 (Fed. Cir. 1988). 
 96. Id. at 587 (citing Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 
F.2d 1367, 1384-85 (Fed. Cir. 1986)). 
 97. See id. at 587. 
 98. Id. at 590. 
 99. Id. at 586. 
 100. Arnold, supra note 45, at 554. 
 101. Id. 
 102. See supra note 98 and accompanying text. 
 103. Dana Corp. v. IPC Ltd. P’ship, 860 F.2d 415 (Fed. Cir. 1988). 
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claimed a valve stem seal for internal combustion engines.104  
The alleged infringer claimed that fluoride treatment of the 
rubber for the seal was essential for the valves to seal 
properly.105  Since Dana’s patent did not state the fluoride 
requirement,106 the infringer asserted the defense that the best 
mode requirement was not satisfied.107 
Dana countered by submitting an article to the court that 
explained that fluoride treatment is known to those skilled in 
the art.108  The Federal Circuit disagreed with Dana’s 
argument, holding that the “best mode requirement is not 
satisfied by reference to the level of skill in the art.”109  Rather, 
the best mode requirement “entails a comparison of the facts 
known to the inventor regarding the invention at the time the 
application was filed and the disclosure in the specification.”110  
Therefore, since the established facts showed that fluoride 
treatment was the best mode, the patent did not satisfy this 
requirement when it failed to make the fluoride disclosure.111 
Next, in Chemcast Corp. v. Arco Industries Corp.,112 the 
patent claimed a sealing member in the “form of a grommet or 
plug button” that was designed to seal an opening in a panel.113  
Unlike its previous holding in Dana,114 the Federal Circuit in 
Chemcast held that “the disclosure required by section 112 is 
directed to those skilled in the art.”115  Therefore, “one must 
consider the level of skill in the relevant art in determining 
whether a specification discloses the best mode.”116  The court 
held there to be a second “objective limitation on the extent of 
the disclosure required to comply with the best mode 
 
 104. See id. at 416. 
 105. Id. at 417. 
 106. See Arnold, supra note 45, at 548 (citing the actual specification). 
 107. Id. 
 108. See Dana, 860 F.2d at 418-19 (Fed. Cir. 1988) (stating that Dana 
argued the best mode requirement was satisfied because the “fluoride 
treatment of Buna-N rubber for seal applications was known to the public [for] 
years . . . . A technical article from Rubber Age magazine and certain expert 
testimony was cited by Dana as supporting the view that such a treatment 
was common to the skilled artisan”).  See also Arnold, supra note 45, at 549. 
 109. See Dana, 860 F.2d at 419. 
 110. Id. 
 111. See id. at 420. 
 112. Chemcast Corp. v. Arco Indus. Corp., 913 F.2d 923 (Fed. Cir. 1990). 
 113. Id. at 924. 
 114. See supra notes 103-111 and accompanying text. 
 115. Chemcast, 913 F.2d at 926 (emphasis added). 
 116. Id. at 927. 
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requirement.”117  The limitation is that the best mode 
requirement is restricted to what is claimed in the invention.118  
Unlike the holding in Christianson v. Colt119, this time the 
Federal Circuit put no parameters on the best mode 
requirement.120 
Therefore, the court summarized a proper best mode 
analysis as having two parts.121  The first component is 
“whether, at the time the inventor filed his patent application, 
he knew of a mode of practicing his claimed invention that he 
considered to be better than any other.”122  This part of the 
analysis is entirely subjective.123  The second part of the 
analysis “compares what [the inventor] knew with what he 
disclosed—is the disclosure adequate to enable one skilled in 
the art to practice the best mode or, in other words, has the 
inventor ‘concealed’ his preferred mode from the ‘public’?”124  
This component is objective, and “depends upon the scope of the 
claimed invention and the level of skill in the art.”125 
Thus, by employing a two-prong analysis, the court found 
the patent in Chemcast invalid.126  The inventor in this case 
knew that the preferred material for the locking portion of the 
grommet was a “rigid polyvinyl chloride plastisol composition, 
having a ‘75 +/-5 Shore D’ hardness.”127  The only compound 
fitting this description was a compound known as R-4467.128  
However, this compound was not disclosed in the 
specification.129  Furthermore, this concealed information was a 
preferred ingredient for making an element of the invention, 
and therefore involved unclaimed subject matter.130  Therefore, 
 
 117. Id. 
 118. Id. 
 119. See supra notes 81-84 and accompanying text. 
 120. See Chemcast, 913 F.2d at 927-28 (Fed. Cir. 1990). 
 121. Id. at 927. 
 122. Id. at 928. 
 123. Id. 
 124. Id. 
 125. Id. 
 126. Id. at 930.  See also Northern Telecom, Inc. v. Datapoint Corp., 908 
F.2d 931 (Fed. Cir. 1990) (a case involving an inventor who failed to disclose 
his preferred embodiment for a specific type of audio tape with different 
features than standard audio tapes.  The court held the patent to be in 
violation of the best mode requirement). 
 127. Arnold, supra note 45, at 559. 
 128. Id. 
 129. See Arnold, supra note 45, at 560 (discussing the actual specification). 
 130. See id. at 561. 
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the Federal Circuit seemed to “adopt a rule that any 
information necessary to practice the best mode of carrying out 
the claimed invention must be disclosed.”131 
As a result of the Federal Circuit’s holdings in the previous 
line of cases,132 it could not be assumed that the best mode 
requirement is a “synonym for disclosure of the ‘preferred 
embodiment’ of the claimed invention.”133  In other words, the 
best mode requirement is not limited to the preferred structure, 
but may include both the preferred method of making the 
invention and the preferred method of using the invention.134 
3. Federal Circuit Opinions Since 1991 
In Wahl Instruments Inc. v. Acvious Inc.,135 the court held 
that the words in 35 U.S.C. § 112 are “not without 
ambiguity.”136  Furthermore, the court found that “the term 
‘mode’ and the phrase ‘carrying out the invention’ are not 
definable with precision.”137 
However, the Federal Circuit in Engel Industries, Inc. v. 
Lockformer Co.138 held that “[t]he best mode inquiry is directed 
to what the applicant regards as the invention, which in turn is 
measured by the claims.”139  Furthermore, the court held that 
unclaimed subject matter is not subject to the best mode 
requirement.140  Therefore, it seems the Federal Circuit has 
been inconsistent in determining whether the best mode 
requirement is ambiguous.141 
Since 1996, the Federal Circuit has found best mode 
requirement violations in three cases.142  The first case was 
United States Gypsum Co. v. National Gypsum Co.,143 decided 
 
 131. See id. 
 132. See supra notes 81-131 and accompanying text. 
 133. Arnold, supra note 45, at 538. 
 134. Id. 
 135. Wahl Instruments Inc. v. Acvious Inc., 950 F.2d 1575 (Fed. Cir. 1991). 
 136. Id. at 1579. 
 137. Id. 
 138. Engel Indus., Inc. v. Lockformer Co., 946 F.2d 1528 (Fed. Cir. 1991). 
 139. Id. at 1531. 
 140. Id. 
 141. See supra notes 135-40 and accompanying text. 
 142. Bayer AG v. Schein Pharms. Inc., 301 F.3d 1306, 1316-19 (Fed. Cir. 
2002). 
 143. United States Gypsum Co. v. Nat’l Gypsum Co., 74 F.3d 1209 (Fed. 
Cir. 1996). 
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by the Federal Circuit in 1996.144  This case involved a 
lightweight joint compound.145  The joint compound contained a 
silicone-treated perlite known as Sil-42 perlite.146  However, the 
patent’s specification did not refer to Sil-42 perlite.147  The 
court determined the inventor selected Sil-42 perlite “because it 
did not require screening and because it significantly improved 
the physical properties of the joint compound.”148  In other 
words, the court found that the inventor “believed that Sil-42 
perlite was essential to improving the invention; the material 
was not selected as a matter of commercial expediency.”149  
Further, the court held that disclosure concerning the best 
mode of practicing an invention is required under 35 U.S.C. § 
112.150  Therefore, the patent was found invalid by the Federal 
Circuit for failure to satisfy the best mode requirement.151 
In Great Northern Corp. v. Henry Molded Products, Inc.,152  
the Federal Circuit held a patent invalid for failure to disclose 
the best mode of carrying out the invention when the 
specification did not refer to diamonds that were used in the 
invention.153  The factual record of the case indicated that, at a 
minimum, the supports for large-diameter rolls could not be 
produced without the diamonds.154  This fact demonstrated that 
the diamonds were critical to practicing the claimed 
invention,155 and were therefore required to be disclosed under 
section 112.156 
In Nobelpharma AB v. Implant Innovations, Inc.,157 the 
patent was on a dental implant that was preferably made of 
 
 144. Id. at 1209. 
 145. Id. at 1210.  Joint compounds are adhesives used in the construction 
of building walls and ceilings to fill and coat the joints between adjacent 
gypsum wallboards.  Id. 
 146. Id. at 1211. 
 147. Id. 
 148. Id. at 1213. 
 149. Id. (emphasis added). 
 150. See id. 
 151. See id. at 1216. 
 152. Great N. Corp. v. Henry Molded Prods. Inc., 94 F.3d 1569 (Fed. Cir. 
1996). 
 153. Id at. 1574. 
 154. Id. at 1572. 
 155. Id. 
 156. See id. (holding that the diamonds related to the best mode for 
practicing the claimed invention). 
 157. Nobelpharma AB v. Implant Innovations Inc., 141 F.3d 1059 (Fed. Cir. 
1998). 
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titanium and a network of particularly-sized and particularly-
spaced micropits.158  These micropits allow a secure connection 
to form between the implant and the growing bone159 in a 
process known as osseointegration.160  The patent neglected to 
mention a variety of machining parameters that were critical to 
the production of a functional dental implant.161  Therefore, the 
Federal Circuit held that the patent did not satisfy the best 
mode requirement.162 
Finally, Eli Lilly & Co. v. Barr Laboratories, Inc.163 
involved a pharmaceutical manufacturer of an antidepressant 
drug (commercially known as Prozac).164  The patent in this 
case disclosed the compound fluoxetine hydrochloride, the 
active form of the drug, but did not disclose the inventor’s 
preferred method for synthesizing the starting material, p-
trifluoromethylphenol,165 necessary to synthesize the drug.166  
The Federal Circuit held that an inventor need not disclose a 
mode for obtaining unclaimed subject matter unless the 
“subject matter is novel and essential for carrying out the best 
mode of the invention.”167 
The court found that Lilly did disclose the preference for 
using p-trifluoromethylphenol when making fluoxetine 
hydrochloride.168  However, they also found that Lilly did not 
disclose the unclaimed method for synthesizing the starting 
material.169  The court went on to hold that “[t]o be sure, if the 
best mode for carrying out a claimed invention involves novel 
subject matter, then an inventor must disclose a method for 
obtaining that subject matter even if it is unclaimed.”170  This 
poses a potential problem however because matter disclosed in 
the specification but not claimed is given to the public and 
therefore cannot be claimed later.171  Nevertheless, in this case, 
 
 158. Id. at 1062. 
 159. Id. 
 160. Id. 
 161. Id. at 1065. 
 162. See id. at 1066. 
 163. Eli Lilly & Co. v. Barr Labs. Inc., 222 F.3d 973 (Fed. Cir. 2000). 
 164. Id. at 973. 
 165. Id. at 978-79. 
 166. See id. at 977. 
 167. Id. at 981. 
 168. Id. at 982. 
 169. Id. 
 170. Id.(emphasis added). 
 171. See Johnston & Johnston Assoc., Inc. v. R.E. Service Co., Inc., 285 
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the court held that the record demonstrated that the starting 
material was not novel.172  This was based on the fact that the 
starting material actually was commercially available.173  
Furthermore, the record included prior art references that 
showed how to prepare the starting material in fluoxetine 
hydrochloride.174 
D. UNITED STATES PATENT AND TRADEMARK OFFICE’S 
INTERPRETATION OF THE BEST MODE REQUIREMENT 
The first step that a patent examiner from the United 
States Patent and Trademark Office (USPTO) must follow is to 
determine how the invention is defined in the claims.175  Under 
the Rules of Examination, the specification “need not set forth 
details not relating to the essence of the invention.”176  In other 
words, unclaimed subject matter that is not related to the 
operation of the invention is not required under the best mode 
requirement.177  However, if the patent applicant “develops 
specific instrumentalities or techniques which are recognized 
by the applicant at the time of filing as the best way of carrying 
out the invention, then the best mode requirement imposes an 
obligation to disclose that information to the public as well.”178 
The examiner should then assume that the best mode is 
disclosed in the application, unless evidence is presented that 
proves otherwise.179  Furthermore, the patent examiner should 
follow the two-prong best mode analysis set out in Chemcast.180  
Only evidence of concealment is to be considered in 
determining the adequacy of a best mode disclosure.181  This 
concealment can either be intentional or accidental.182  This 
evidence of concealment must “tend to show that the quality of 
an applicant’s best mode disclosure is so poor as to effectively 
 
F.3d 1046, 1051 (Fed. Cir. 2002). 
 172. See Eli Lilly, 222 F.3d at 982. 
 173. Id. 
 174. Id. 
 175. MANUAL OF PATENT EXAMINING PROCEDURE § 2165.01 (2003) 
[hereinafter MANUAL]. 
 176. Id. 
 177. Id. 
 178. Id at § 2165.02. 
 179. Id. at § 2165.03. 
 180. See id.; see also supra notes 120-26 and accompanying text. 
 181. See MANUAL, supra note 175, at § 2165.04. 
 182. See id. 
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result in concealment.”183 
In conclusion, Congress has extensively dealt with the best 
mode requirement through several acts leading up to the 
Patent Act of 1952.184  Furthermore, the courts have 
interpreted the best mode requirement at length since 
Congress established the Patent Act in 1952.185  In light of this 
legislative history and judicial precedent, the Federal Circuit 
decided Bayer v. Schein.186 
II. THE FEDERAL CIRCUIT’S RESOLUTIONS IN BAYER V. 
SCHEIN 
A. THE BACKGROUND HOLDINGS OF THE FEDERAL CIRCUIT 
The Federal Circuit decided Bayer v. Schein on August 9, 
2002.187  The court first described the basis for Schein’s 
assertion of Bayer’s patent invalidity under 35 U.S.C. 
§102(d).188  Section 102(d) provides in relevant part: 
A person shall be entitled to a patent unless . . . the invention was 
first patented or caused to be patented, or was the subject of an 
inventor’s certificate, by the applicant . . . in a foreign country prior to 
the date of the application for patent in this country on an application 
for patent or inventor’s certificate filed more than twelve months 
before the filing of the application in the United States .189 
Schein made two allegations in support of invalidity under 
section 102(d).  First, Schein argued that Bayer filed foreign 
patent applications on Cipro more than one year prior to 
October 22, 1982.190  October 22, 1982 was the earliest priority 
date of the ‘923 application that issued as the ‘444 patent.191  
Second, the foreign patent applications issued before October 
22, 1982.192  Therefore, the ‘444 patent was filed more than one 
year after the filing of the foreign patents and is invalid under 
section 102(d), unless Bayer can rely upon an earlier filing 
 
 183. Id. 
 184. See supra notes 47-61 and accompanying text. 
 185. See supra notes 62-174 and accompanying text. 
 186. Bayer AG v. Schein Pharm, Inc., 301 F.3d 1306 (Fed. Cir. 2002). 
 187. Id. at 1306. 
 188. See id. at 1312. 
 189. Id. at 1312 (quoting 35 U.S.C. § 102(d) (2000)). 
 190. See id. at 1312-13. 
 191. Id. 
 192. Id. 
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date.193 
However, Bayer countered that the ‘444 patent is not 
invalid under section 102(d) because the ‘444 patent can claim 
priority to the filing date of the ‘560 application under 35 
U.S.C. § 120.194  Section 120 provides in relevant part: 
An application for patent for an invention disclosed in the manner 
provided by the first paragraph of section 112 of this title in an 
application previously filed in the United States, . . . which is filed by 
an inventor or inventors named in the previously filed application 
shall have the same effect, as to such invention, as though filed on the 
date of the prior application, if filed before the patenting or 
abandonment or termination of proceedings on the first 
application.195 
Bayer argued that under section 120, the ‘444 patent can claim 
priority to August 13, 1982, the filing date of the ‘560, 
application,196  Since this date is within a year of the filing date 
of the foreign patents, Bayer argued that 102(d) should not 
apply.197  However, the court stated that section 120 only 
applies if the earlier application fulfills the disclosure 
requirements of 35 U.S.C. § 112.198  Therefore, “Bayer may 
defeat the 102(d) bar . . . only if the ‘560 application fulfills the 
disclosure requirements of section 112.”199 
Schein argued that the ‘560 application did not satisfy 35 
U.S.C. § 112 because it failed to disclose the best mode 
contemplated by Dr. Grohe for making Cipro.200  According to 
Schein, the application failed to do so because it did not 
“disclose the synthesis of the Klauke compound or the use of 
the cycloaracyclation reaction to make 6-FQA.”201  However, 
both of these compounds are intermediates which are not 
claimed in the ‘444 patent.202  Nevertheless, Schein asserted 
that 6-FQA and its synthesis via cycloaracyclation of the 
Klauke compound is novel and therefore the preferred method 
of making them is required to be disclosed under section 112 in 
order to adequately describe the best mode of synthesizing 
 
 193. Id. at 1313. 
 194. Id. 
 195. Id. (quoting 35 U.S.C. § 120 (2000)). 
 196. Id. at 1313. 
 197. See supra note 15. 
 198. Bayer, 301 F.3d at 1313. 
 199. Id. 
 200. Id. 
 201. Id; see also supra notes 5-10 and accompanying text. 
 202. Bayer, 301 F.3d at 1313. 
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Cipro.203 
In its analysis, the Federal Circuit stated, “compliance 
with the best mode requirement requires disclosing the 
inventor’s preferred embodiment of the claimed invention.”204  
In addition, the court stated, “cases examining the scope of the 
best mode requirement demonstrate that the best mode 
disclosure requirement only refers to the invention defined by 
the claims.”205  Finally, the Federal Circuit held that the 
“existence of a best mode is a purely subjective matter 
depending upon what the inventor actually believed at the time 
the application was filed . . . . [Therefore], the best mode 
requirement . . . cannot be met by mute reference to the 
knowledge of one of skill in the art.”206 
Furthermore, the court found that the best mode 
requirement does not “demand disclosure of every preference 
an inventor possesses as of the filing date . . . .”207  The Federal 
Circuit explained that “[a]s is always the case, the text of the 
statute provides the proper boundaries of the disclosure 
requirement.”208  The court went on to hold that “[s]ection 112 
only demands disclosure of ‘the best mode contemplated by the 
inventor of carrying out his invention.’”209 
Nevertheless, the court admitted that it has “‘found 
violations of the best mode requirement for failure to disclose 
subject matter not strictly within the bounds of the claims.’”210  
The court found that there had been seven occasions in the 
history of the Federal Circuit and its predecessor courts when 
patents had been invalidated for failure to meet the best mode 
requirement.211  The court found that these cases “involved 
either failure to disclose a preferred embodiment, or else failure 
to disclose a preference that materially affected making or 
using the invention.”212 
 
 203. Id. (drawing on the holding in Eli Lilly, 251 F.3d at 964 (Fed. Cir. 
2001).  See also supra note 170 and accompanying text. 
 204. Bayer, 301 F.3d at 1316 (emphasis added). 
 205. Id. at 1315. 
 206. Id. at 1314. 
 207. Id. at 1314-15. 
 208. Id. at 1315. 
 209. Bayer, 301 F.3d at 1315 (quoting 35 U.S.C. § 112 (1994)) (alteration in 
original). 
 210. Id. at 1316 (quoting Teleflex, Inc. v. Ficosa N. Am. Corp., 299 F.3d 
1313, 1331 (Fed. Cir. 2002)). 
 211. Id. 
 212. Id. 
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B. THE CASE ANALYSES OF THE FEDERAL CIRCUIT IN BAYER V. 
SCHEIN 
The first case discussed by the Federal Circuit was 
Spectra-Physics.213  The Federal Circuit stated that although 
the patent specification at issue in Spectra-Physics disclosed 
the preference for using TiCuSil as a brazing material, it did 
not disclose the parameters for performing the TiCuSil brazing 
cycle developed by the inventor.214  Since the patent 
specification stressed the importance of brazing in obtaining 
efficiency and reliability of the claimed laser, the “failure to 
disclose the actual method of brazing preferred by the inventor 
rendered the patent claims invalid for ‘failure to disclose the 
best mode contemplated by the inventors for practicing 
their . . . inventions.’”215 
The Federal Circuit then discussed Dana Corp.216  In this 
case, the invention was a valve stem seal for an internal 
combustion engine.217  The inventor found that a 60-second 
fluoride surface treatment was necessary for the seal to 
function without leaking.218  According to the Federal Circuit, 
“the undisclosed fluoride surface treatment had a material 
effect on the properties of the claimed invention.”219  Since “the 
inventor ‘believed that the best way of carrying out his 
invention included fluoride treating the surface of the valve 
seals,’” and the “specification never ‘disclosed that a fluoride 
treatment must or even should be applied’ . . . as preferred by 
the inventor,” the patent was held to be invalid for failure to 
disclose the best mode.220 
Next, the court discussed Northern Telecom.221 In this case, 
the defendant raised a best mode challenge to claims directed 
to capturing data on magnetic tape cassettes.222  The inventor 
preferred certain audio tapes with specific yield strength and 
magnetic characteristics which were different from standard 
 
 213. Id. 
 214. Id. at 1316.  See supra notes 85-94 and accompanying text. 
 215. Bayer, 301 F.3d at 1316-17 (quoting Spectra-Physics, Inc. v. Coherent, 
Inc., 827 F.2d 1524, 1537 (Fed. Cir. 1987)). 
 216. Id. at 1317.  See supra notes 103-11 and accompanying text. 
 217. Bayer, 301 F.3d at 1317. 
 218. Id. at 1317. 
 219. Id. 
 220. Id. (quoting Dana Corp. v. IPC Ltd. P’ship, 860 F.2d at 419-20). 
 221. Id.  See supra text accompanying note 126. 
 222. Bayer, 301 F.3d at 1317. 
GILBERT 12·14·2003  12:14 PM 
108 MINNESOTA INTEL. PROPERTY REVIEW [Vol. 5:1 
 
audio tapes.223  The specification however disclosed neither the 
inventor’s specifications for the preferred tape nor the identity 
of the brand on the market that met the inventor’s 
specifications.224  The court held the patent in violation of the 
best mode requirement because the “inventor had developed a 
preferred embodiment of his invention that used a very specific 
type of audiotape, and failure to disclose that preferred 
embodiment . . . .”225 
The fourth case discussed by the Federal Circuit is 
Chemcast.226  In this case, the claim was directed to a grommet 
and the inventor had a preference for a particular material for 
making the locking portion of the grommet.227  The patent’s 
disclosure was found to be deficient for failure to disclose this 
fact in the specification.228  In concealing the preferred 
embodiment, the best mode requirement was not satisfied, and 
the claims were invalid229 
The fifth case discussed by the Federal Circuit in Bayer is 
Gypsum.230 Gypsum dealt with the validity of a claim directed 
to a compound that contained an “expanding perlite.”231  The 
court stated that the inventor “‘believed that Sil-42 perlite was 
essential to improving the invention; the material was not 
selected as a matter of commercial expediency.’”232  Therefore, 
by not disclosing the Sil-42 perlite, the patent did not disclose 
the best mode of carrying out the inventor’s preferred 
embodiment, and was thus held invalid.233 
The Federal Circuit also discussed Great Northern Corp.234  
In this case, the patent specification failed to disclosed diamond 
indentations that were “crucial to producing a usable version of 
the invention.” because without them, the support, “simply 
collapsed under the weight of the rolls it was supposed to 
 
 223. Id. 
 224. Id. 
 225. Id. 
 226. Id.  See supra notes 112-31 and accompanying text. 
 227. Bayer, 301 F.3d at 1317. 
 228. Id. 
 229. Id. 
 230. Id.  See supra notes 142-51 and accompanying text. 
 231. Bayer, 301 F.3d at 1318. 
 232. Id. (emphasis added) (quoting United States Gypsum Co. v. Nat’l 
Gypsum Co., 74 F.3d 1209, 1213 (Fed. Cir. 1996)). 
 233. See id. at 1318. 
 234. Id.  See supra notes 152-56 and accompanying text. 
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hold.”235  The claims were held to be invalid because the 
diamonds that materially affected the properties of the claimed 
invention were not disclosed and resulted in a failure to satisfy 
the best mode requirement.236 
Lastly, the Federal Circuit discussed Nobelpharma.237  In 
this case, the patent claimed “an element intended for 
implantation in to bone tissue” that contained micropits.238  
The production of the implant depended decisively on a number 
of undisclosed machine parameters.239  The undisclosed 
parameters were said to be “related to manufacture of the 
claimed implant, and were critical to production of a functional 
implant.”240  Since the undisclosed preference materially 
affected the properties of the invention, failure to disclose it 
resulted in a violation of the best mode requirement.241 
C. ACCORDING TO THE FEDERAL CIRCUIT, BAYER DID NOT 
VIOLATE THE BEST MODE REQUIREMENT IN ITS ‘560 PATENT 
According to the Federal Circuit, the first step in any best 
mode analysis is to identify the invention recited in the 
claims.242  The Federal Circuit noted that the claims of the ‘444 
patent involve “compositions of matter that either comprise or 
consist solely of the target antibiotic compound—in this case 
ciprofloxacin.”243  Furthermore, the court noted that the claims 
do not recite 6-FQA or any other starting material.244  Thus, 
 
 235. Bayer, 301 F.3d at 1318. 
 236. Id. 
 237. Id.  See supra notes 157-62 and accompanying text. 
 238. Bayer, 301 F.3d at 1318. 
 239. Id. 
 240. Id. at 1318-19. 
 241. Id. at 1319. 
 242. See id. at 1320 (discussing N. Telecom Ltd. v. Samsung Elec. Co., 215 
F.3d 1281, 1286-87 (Fed Cir. 2000)).  Bayer described the holding in N. 
Telecom as follows: 
[T]he first step in a best mode inquiry, before application of the 
familiar two-part best mode test, must be to define the invention by 
construing the claims. Definition of the invention ‘is a legal exercise, 
wherein the ordinary principles of claim construction apply.’ Defining 
the invention by analyzing the claim language is a crucial predicate to 
the factual portions of the best mode inquiry because it ensures that 
the finder of fact looks only for preferences pertaining to carrying out 
the claimed invention. 
Id. (emphasis in original) (quoting N. Telecom, 215 F.3d at 1286-87). 
 243. Id. 
 244. Id. at 1321. 
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“the invention . . . consists of the final antibiotic product and 
not the starting materials.”245  In addition, the court noted that 
the inventor had a preferred method of making ciprofloxacin by 
“manipulating 6-FQA by reacting it with piperazine.”246  
Furthermore, the ‘560 application did not disclose either the 
Klauke compound or its use in making 6-FQA, which are both 
intermediate steps in the synthesis of Cipro.247 
However, the Federal Circuit held that Bayer’s failure to 
disclose Dr. Grohe’s preferred method of making 6-FQA was 
not a violation of the best mode requirement.248  The court 
stated that only “[p]references that are reflected in a preferred 
embodiment or that relate to making or using the invention 
and have a material effect on the properties of the claimed 
invention” are required to be disclosed.249  The court found that 
failure to disclose the method of making 6-FQA was not fatal 
because it had no material effect on the properties of Cipro.250  
As a result, the court found this case “clearly distinguishable 
from the four cases in which this court has found a best mode 
violation where an undisclosed preference clearly had a 
material affect on the properties of the claimed invention.”251 
Schein raised the argument that disclosure of Dr. Grohe’s 
preferred method of producing 6-FQA is mandatory because it 
is novel.252  Schein based this contention on the Federal 
Circuit’s holding in Eli Lilly.253  However, the court held that 
Schein misunderstood the Federal Circuit’s holding in Eli 
Lilly.254  The court in Bayer explained that the Federal Circuit 
in Eli Lilly “merely acknowledged that when a novel compound 
is necessary to practice the best mode, one of skill in the art 
must be able to obtain that compound.”255  Therefore, the 
 
 245. Id. 
 246. Id. 
 247. Id. 
 248. See id. at 1323. 
 249. Id. at 1321. 
 250. See id. at 1321-22. 
 251. Id.  These four cases are Spectra-Physics, Nobelpharma, Dana, and 
Great Northern.  See supra section II.B. 
 252. Bayer, 301 F.3d at 1322. 
 253. Id; see supra notes 163-74 and accompanying text. 
 254. Bayer, 301 F.3d at 1322 (“Schein understands Eli Lilly to stand for the 
proposition that the best mode of obtaining novel subject matter necessary to 
practice the invention must be disclosed.  Schein has misunderstood the 
impact of our statements in Eli Lilly”). 
 255. Id. at 1322. 
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following statements in Eli Lilly, such as “a method for 
obtaining that subject matter” and “a mode for obtaining 
unclaimed subject matter” refer only to a requirement that the 
best mode be enabled by the specification.256  Since the ‘560 
patent contains an enabling disclosure of 6-FQA, it complies 
with the holding in Eli Lilly as interpreted by the Federal 
Circuit.257 
In conclusion, the Federal Circuit held in Bayer that Dr. 
Grohe’s preferred method of making 6-FQA does not materially 
affect the production of Cipro.258  Therefore, its disclosure is not 
required to comply with the best mode requirement.259  Since 
the ‘560 application is in compliance with 35 U.S.C. §112, 
paragraph 1, the ‘444 patent can claim the filing date of the 
‘560 application under 35 U.S.C. §120.260  Moreover, because 
this filing date is well within the filing date of the first foreign 
patent, the issuance of those foreign patents does not invalidate 
the ‘444 patent under 35 U.S.C. §102(d).261 
III. WHY THE COURT ERRED IN BAYER V. SCHEIN 
In Bayer, the Federal Circuit stated that 35 U.S.C. § 112 
demands disclosure of the best mode the inventor contemplated 
for carrying out the invention.262  The court noted it had held 
that nondisclosure of unclaimed subject matter violated the 
best mode requirement when the specification failed to disclose 
a preferred embodiment or else failed to disclose a preference 
that materially affected making or using the invention.263  The 
court subsequently held in the instant case that the ‘560 patent 
from which the ‘444 patent claimed benefit did not violate the 
best mode requirement, because the unclaimed subject matter 
did not materially affect making or using the claimed invention 
nor was it a preferred embodiment of the claimed invention.264 
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A. THE KLAUKE COMPOUND AND 6-FQA MATERIALLY AFFECT 
THE PRODUCTION OF CIPRO 
Analysis of the facts shows that the Klauke compound 
materially affected and was vital to the final synthesis of Cipro.  
Grohe’s initial method of synthesizing 6-FQA was 
unsuccessful.265  The Klauke compound was the only structure 
known by Grohe that could be used to synthesize 6-FQA.266  As 
such, without the Klauke compound, 6-FQA was an obscurity to 
Dr. Grohe and without 6-FQA, the synthesis of Cipro would 
have been impossible for him.267  Therefore, the Klauke 
compound and the preferred synthetic route to 6-FQA by Grohe 
were essential to the production of Cipro.  Since essential steps 
in a process materially affect the final production of a product, 
these two properties of the final invention should have been 
disclosed in the specification in order to satisfy the best mode 
requirement as interpreted by the Federal Circuit in Bayer.268 
The Federal Circuit looked to several cases to support its 
holding that the ‘560 patent did not violate the first prong of 
the best mode requirement.269  These cases are outlined in 
sections I and II of this Comment.  Like Bayer, these cases all 
involved unclaimed subject matter in the specification.270  
However, unlike Bayer, the Federal Circuit found best mode 
violations in every one by holding that the unclaimed subject 
matter materially affected the claimed invention.271  In Bayer, 
the court erred by not finding a direct correlation between the 
facts of those cases and the facts in Bayer. 
The facts of Spectra-Physics are essentially the same as the 
facts of Bayer.272  Both cases involved a certain method that 
was optimal for ultimately producing the claimed invention.273  
In Spectra-Physics, the inventor had a preferred method for 
utilizing the TiCuSil brazing material.274  In Bayer, it was the 
use of the Klauke compound and the synthetic pathway of 6-
 
 265. Id. at 1310. 
 266. See id. 
 267. See id. 
 268. See supra notes 135-74 and accompanying text. 
 269. See supra notes 213-61 and accompanying text. 
 270. See supra notes 213-41 and accompanying text. 
 271. See supra notes 213-41 and accompanying text. 
 272. See supra notes 85-94, 187-212 and accompanying text. 
 273. See supra notes 85-94, 187-212 and accompanying text. 
 274. See supra note 88 and accompanying text. 
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FQA.275  In Spectra-Physics, the Federal Circuit made a clear 
holding that would directly support a best mode violation by 
Bayer – if the patent applicant develops specific 
instrumentalities or techniques which are recognized as the 
best way of carrying out the invention, the best mode 
requirement demands disclosure of the preference.276  
Therefore, the Federal Circuit did not make an adequate 
comparison between Spectra-Physics and Bayer, applying 
Spectra-Physics incorrectly to the facts of Bayer.  Clearly, the 
Klauke compound is a specific compound (instrumentality) 
developed by Bayer to synthesize Cipro.  Furthermore, the 
Klauke compound is the best way, if not the only way, of 
ultimately carrying out the claimed invention.277  Therefore, 
according to the Federal Circuit’s logic in Spectra-Physics, 
Bayer violated the best mode requirement of 35 U.S.C. § 112. 
The Federal Circuit also erred in its analysis of Bayer in 
relation to Dana Corp.278 In Dana, a fluoride treatment was 
necessary in order for the valve to work properly.279  Thus, the 
treatment materially affected the claimed invention.  In Bayer, 
the Klauke compound was necessary for the synthesis of 6-
FQA, which was in turn essential to the production of the 
claimed invention, Cipro.280  This was exactly like the 
undisclosed fluoride treatment in Dana.  Therefore, when the 
court compared the facts in Bayer to the facts and holding in 
Dana, it should have found that Bayer violated the best mode 
requirement. 
The Federal Circuit also erred in its analysis of Bayer in 
relation to Great Northern Corp.281  In Great Northern, 
diamond indentations used to stabilize the molded pulp roll 
support were crucial to producing a workable version of the 
invention.282  Without their disclosure, the Federal Circuit held 
that Great Northern’s patent failed the best mode requirement, 
because the diamond indentations materially affected the 
claimed invention.283  The Klauke compound and the synthetic 
 
 275. See supra notes 268-70 and accompanying text. 
 276. See supra note 92 and accompanying text. 
 277. See supra notes 265-68 and accompanying text. 
 278. See supra notes 216-20 and accompanying text. 
 279. See supra notes 218-19 and accompanying text. 
 280. See supra notes 265-68 and accompanying text. 
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route are the “diamond indentations” of Bayer.  Without these 
parts of the claimed invention, there would be no usable 
version of Cipro.  Thus, the court should have also found a best 
mode violation in Bayer when comparing the facts of this case 
to Great Northern. 
Finally, in Nobelpharma, the court found a best mode 
violation when the inventor failed to disclose a subjective 
preference in the production of the claimed invention, a dental 
implant.284  The patentee failed to disclose a variety of specific 
machining parameters required in order to produce a 
functional implant.285  By analogy, the Klauke compound and 
synthesis of 6-FQA are the undisclosed “machining 
parameters” required to produce Cipro.  Therefore, just as the 
parameters in Nobelpharma materially affected the claimed 
invention, the Klauke compound and 6-FQA synthesis 
materially affect Cipro. 
B. THE KLAUKE COMPOUND IS A PREFERRED EMBODIMENT OF 
CIPRO 
In Northern Telecom, the Federal Circuit found a best 
mode violation because a preferred embodiment of the claimed 
invention used a specific type of audiotape, which was not 
disclosed in the specification 286  The court in Bayer did not 
appreciate the relationship between these two cases.  The 
Klauke compound was a specific precursor to the synthesis of 6-
FQA.287  Dr. Grohe’s standard method of synthesizing bicyclics 
involved beginning with a starting material.288  He was 
unsuccessful in producing the material needed for 6-FQA and 
enlisted the help of a colleague.289  This method involved the 
specific use of the Klauke compound to synthesize 6-FQA.290  It 
is undisputed that Dr. Grohe had a preference prior to August 
13, 1981, for a class of starting materials including the Klauke 
compound.291  Therefore, the court once again should have 
found a best mode violation, because the Klauke compound was 
a specific, preferred embodiment of the claimed invention. 
 
 284. See supra notes 237-241 and accompanying text. 
 285. See supra notes 237-241 and accompanying text. 
 286. See supra notes 221-25 and accompanying text. 
 287. See Bayer, 301 F.3d at 1310. 
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 290. See id. 
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C. BAYER IN LIGHT OF THE POLICY OF THE BEST MODE 
REQUIREMENT 
The disclosure requirement set out in 35 U.S.C. § 112 
ensures that every essential aspect of the invention is made 
public with the granting of the patent.292  The entry of the 
information into the public domain is essential to promoting 
the sharing and expansion of knowledge and the benefits that 
flow there from.  In the scientific community, for example, 
scientists share knowledge through journals and 
correspondence with one another.  This dissemination of 
information advances the progress of science–one scientist 
builds on the research and discoveries of another scientist and 
so forth.  In a similar way, progression of knowledge flows from 
patented inventions–one inventor builds on a preceding 
inventor’s discoveries, thus advancing science, technology, and 
ultimately society. 
In Bayer, disclosure of the intermediates in the synthesis of 
Cipro was not required according to the Federal Circuit.293  
Without their disclosure, however, the public is unaware of how 
to make Cipro according to Dr. Grohe’s preferred embodiment.  
This lack of disclosure may seem harmless if one assumes most 
individuals in society are unlikely to synthesize Cipro.  
However, pharmaceutical companies and scientists are also 
deprived of the pathway for the synthesis of 6-FQA from the 
Klauke compound.  If these two entities were granted this 
knowledge by its disclosure in the ‘560 patent’s specification, 
they might have been able to build on the knowledge of Bayer 
and synthesize new and improved antibiotics or other drugs.  
Thus, what may seem harmless at first could have heavy 
societal consequences. 
D. BAYER IN LIGHT OF PRECEDENT 
The courts early on recognized the social policy of the best 
mode requirement and recognized a quid pro quo status 
between patentee and the public.294  In In re Gay, the United 
States Court of Customs and Patent Appeals held that a 
patentee might not be allowed to conceal an embodiment of his 
invention from the public in order to retain possible future 
 
 292. See supra notes 34-38 and accompanying text. 
 293. Bayer, 301 F.3d at 1323. 
 294. See supra notes 62-63 and accompanying text. 
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benefits from such withholding.295  Therefore, as early as 1962, 
the courts recognized the quid pro quo between patentee and 
the public.  The court determined that the patent system, in 
addition to spreading knowledge that advances science and 
technology, sets up a social hierarchy between the patentee and 
the public.  The patentee will be granted a limited patent upon 
one fundamental consideration–furnishing the public with the 
means to reproduce the invention at a later time.  The best 
mode requirement is a vital aspect of this exchange between 
the patentee and public, because it ensures that the public will 
be equipped with the inventor’s preferred method of producing 
the invention.  The hope is that the public will eventually be 
able to reproduce the invention with the same amount of effort 
as the inventor. 
As applied to Bayer, this judicial interpretation of policy 
behind the best mode requirement should have resulted in a 
holding that invalidated Bayer Corp’s patent for failure to 
disclose the Klauke compound and the pathway to synthesis of 
6-FQA.  Without this disclosure, the public is not granted quid 
pro quo.  Bayer reaps the benefits of its patent monopoly, but 
the public is not furnished with complete knowledge to produce 
Cipro after Bayer’s patent monopoly expires.  Thus, the social 
hierarchy set up by 35 U.S.C. § 112 fails in practice. 
The courts have also been deliberate in differentiating 
between essential and non-essential elements in their 
requirements for patent disclosure.  For example, in Randomex, 
a pivotal case in best mode jurisprudence, the Federal Circuit 
made a concrete distinction between those essential aspects of 
an invention that require disclosure and non-essential ones 
that do not, explaining that a patentee of an internal 
combustion engine would, for example, be required to disclose 
the fuel on which the engine runs because it is essential to the 
invention.296  However, under the best mode requirement, the 
patentee would not be required to disclose the process for 
refining fuel because it is not essential to the engine.297  To the 
extent that the engine has fuel to run as envisioned, it is 
irrelevant how the fuel was produced.298 
Cases prior to Randomex also expressed this distinction 
 
 295. See In re Gay, 309 F.2d 769, 774 (C.C.P.A. 1962). 
 296. See supra notes 95-97 and accompanying text. 
 297. See supra note 98 and accompanying text. 
 298. See supra notes 98-102 and accompanying text. 
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between essential embodiments of an invention and expendable 
ones.  In Flick-Reedy, the court found a special tool used to 
create the unique seal that was an essential element of the 
patent also to be indispensable element of the claimed 
invention.299  Therefore, its disclosure was required in order to 
satisfy the best mode requirement.300  In International 
Telephone the court again made this distinction, however here 
it found the undisclosed elements to be nonessential to the 
production of the invention, and their disclosure was not 
required.301 
In Bayer, the Klauke compound and synthesis of 6-FQA 
upon which the production of Cipro depends and from which it 
is synthesized can be analogized to the fuel of Randomex and 
the special tool of Flick-Reedy.  Without these two compounds, 
Cipro would not exist as synthesized under Dr. Grohe.302  These 
two intermediates of Cipro are needed for its efficient 
production; therefore they must be disclosed under the Federal 
Court’s analyses and holdings in Randomex, Flick-Reedy, and 
International Telephone and its articulation of the essential 
element requirement.303 
The Federal Circuit has articulated further broad 
circumstances when information must be disclosed.  In 
Chemcast, in addition to establishing the two-prong analysis 
that the Federal Circuit currently follows,304 the court further 
held that any information necessary to practice the best mode 
of the invention must be disclosed.305  This holding is simply 
another way of stating the distinction made in Randomex.  In 
Chemcast, the patentee did not disclose a preferred ingredient 
for making an element of the invention and the court held that 
the best mode requirement was not satisfied.306  Likewise, in 
Bayer, the patentee failed to disclose a preferred ingredient–the 
Klauke compound necessary to make an element of the 
intermediate, 6-FQA.307  Under the Federal Circuit’s precedent 
in Chemcast, Bayer violated the best mode requirement. 
 
 299. See supra notes 64-69 and accompanying text. 
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Finally, in United States Gypsum, the Federal Circuit held 
that in addition to the disclosure of essential aspects of the 
claimed invention, disclosure of the best mode of practicing an 
invention is required under 35 U.S.C. § 112.308  Thus, the court 
interpreted the text of the best mode requirement as requiring 
disclosure of methods of producing or bringing the claimed 
invention to fruition.  In Bayer, the method of practicing the 
claimed invention was to use the Klauke compound to produce 
6-FQA and then to use 6-FQA to synthesize Cipro.309  This was 
the best mode of practicing the claimed invention as conceived 
by Dr. Grohe at the time of patent application.310  Therefore, its 
disclosure is required according to Gypsum and the text of 35 
U.S.C. § 112. 
E. 35 U.S.C. § 112 MAY NOT PERTAIN ONLY TO CLAIMED 
SUBJECT MATTER 
The Federal Circuit in Bayer held that 35 U.S.C. § 112 
“only demands disclosure of ‘the best mode contemplated by the 
inventor of carrying out his invention.’”311  However, the court 
previously found the phrase “carrying out his invention” in § 
112 ambiguous.312  In Wahl Instruments, the court found that 
the phrases “mode” and “carrying out the invention” were not 
precisely definable.313  However, a second judicial 
interpretation held that the phrase applied only to the claimed 
invention.314  The first case to address the issue of whether the 
best mode requirement is limited to the claimed invention was 
Christianson.315  However, this decision was made in reference 
to mass production and sales to customers only.316  Therefore, it 
was a limited holding that has gained widespread recognition 
in the Federal Circuit as binding law in a variety of cases that 
do not involve mass production or sales to customers. 
Therefore, since the phrases “carrying out the invention” 
and “mode” are ambiguous, there is support for the contention 
 
 308. See supra notes 34, 143-51 and accompanying text. 
 309. See supra notes 265-68 and accompanying text. 
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that they need not apply only to the claimed invention.  There 
is no direct language in 35 U.S.C. § 112, ¶ 1, which explicitly 
refers to the “claimed invention.”  This statute refers only to 
“the best mode of carrying out the invention.”317  Further, there 
is no legislative history that mandates the restriction of § 112 
to the claimed invention.318 
Therefore, Bayer Corp. may have violated the best mode 
requirement under 35 U.S.C. § 112, ¶ 1, regardless of whether 
the Klauke compound or 6-FQA synthesis were or were not 
undisclosed preferred embodiments or undisclosed 
intermediates which materially affected the production of 
Cipro.  According to the text of § 112 and the legislative history 
of the Patent Act, Bayer is required to disclose any preferred 
method of producing Cipro without regard to its remoteness to 
the claimed invention. 
F. THE IMPACT OF ELI LILLY ON BAYER 
Novel subject matter alone may require disclosure. The 
facts of Eli Lilly are similar to those of Bayer.319  The inventor 
in Eli Lilly disclosed the claimed invention, Prozac, but did not 
disclose the inventor’s preferred method for synthesizing the 
starting material needed to make Prozac.320  The Federal 
Circuit held that any best mode involving novel subject matter 
must be disclosed even if the novel subject matter is 
unclaimed321 and held, in this case, that the unclaimed subject 
matter was not novel, because it was commercially available 
from more than one supplier.322 
In Bayer, however, the starting materials for the synthesis 
of Cipro were not commercially available.323  In fact, the Klauke 
compound had to be synthesized by another scientist at Bayer 
because Dr. Grohe was having difficulty synthesizing a 
precursor to 6-FQA.324  If the Klauke compound had been 
commercially available, Dr. Grohe most likely would have been 
able to obtain it with more ease than actually occurred.  
Therefore, since the two intermediates of Cipro were novel 
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under the Federal Circuit’s analysis in Eli Lilly, they were 
required to be disclosed in the specification in order to comply 
with the best mode requirement of 35 U.S.C. § 112, ¶1. 
G. THE FEDERAL CIRCUIT’S INTERPRETATION OF THE BEST 
MODE REQUIREMENT IN BAYER COMPARED TO THE UNITED 
STATES PATENT AND TRADEMARK OFFICE’S INTERPRETATION OF 
35 U.S.C. § 112, ¶ 1. 
The USPTO’s interpretation of the best mode requirement 
is quite similar to the Federal Circuit’s interpretation of the 
best mode requirement.325 However, the USPTO expressly 
recognizes that if the patent applicant develops specific 
techniques that he or she recognizes as the best mode of 
carrying out the invention, these must be disclosed in the 
specification under the patentee’s obligation to the public to 
disclose this preferred technique.326 
Therefore, under the USPTO guidelines, Bayer Corp would 
likely be required to disclose the Klauke compound and 
synthetic route of 6-FQA in the ‘560 patent, since these 
intermediates were developed by Dr. Grohe as specific 
techniques to synthesize Cipro. 
IV. CONCLUSION 
In Bayer v. Schein, the Federal Circuit held that a 
pharmaceutical company did not violate the best mode 
requirement of 35 U.S.C. § 112, ¶ 1, when it failed to disclose 
two intermediates in the synthesis of Cipro.  The court relied 
on past precedent to conclude that unclaimed subject matter 
need only be disclosed for best mode purposes when it is a 
concealed preferred embodiment of the claimed invention or 
when it materially affects the making or using of the claimed 
invention.  The Federal Circuit held that the two 
intermediates, the Klauke compound and the synthetic route of 
6-FQA, both unclaimed, were neither a preferred embodiment 
nor did they materially affect the claimed invention, Cipro. 
A closer analysis of the facts of precedent cases suggests 
that the Federal Circuit erred in its holding.  As analogized to 
Spectra-Physics, Dana, Great Northern, and Nobelpharma, the 
two intermediates in question in Bayer do materially affect the 
making or using of Cipro.  Further, like the invention in 
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Northern Telecom, they are both preferred embodiments of the 
claimed invention.  Analysis of Federal Circuit precedent leads 
to these two conclusions.  Additionally, other Federal Circuit 
precedent, and USPTO rules, mandate the disclosure of the 
Klauke compound and 6-FQA under 35 U.S.C. § 112, ¶ 1.  
Finally, there is good social policy behind the best mode 
requirement of disclosure of all necessary and important 
subject matter.  For these reasons, the public should be given 
the chance to know how to synthesize Cipro from the Klauke 
compound and the synthesis of 6-FQA. 
 
